Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Lupin Australia Pty Limited

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (288)
ARTG (239)
Prescription medicine registration (18)

Date

2024 (48)
2023 (47)
2022 (222)
2021 (8)
2020 (33)
2019 (21)
2018 (32)
2017 (11)
2016 (10)
2014 (27)
2013 (17)
2012 (2)
2011 (16)
2010 (19)
2009 (1)
2008 (21)
2007 (5)
2001 (1)
1991 (4)

Results for "[search-keyword]"

Search

Sponsor content

545 result(s) found, displaying 21 to 30

FENOFIBRATE-WGR fenofibrate 145 mg film-coated tablet blister pack (442651)

21 May 2024

ARTG

Australian Register of Therapeutic Goods (ARTG) information for FENOFIBRATE-WGR fenofibrate 145 mg film-coated tablet blister pack.
RIVAROXABAN GH rivaroxaban 20 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
RIVAROXABAN GH rivaroxaban 15 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
RIVAROXABAN GH rivaroxaban 10 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
RIVAROXABAN GH rivaroxaban 2.5 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
FENOFIBRATE GENERICHEALTH fenofibrate 145 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
FENOFIBRATE GENERICHEALTH fenofibrate 48 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
SUGAMMADEX GH sugammadex (as sodium) 500 mg/5 mL solution for injection vial Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
SUGAMMADEX GH sugammadex (as sodium) 200 mg/2 mL solution for injection vial Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited
TENOFOVIR EMT GH tenofovir disoproxil phosphate and emtricitabine 291mg/200mg film coated tablets Cancelled under Section 30(1)(c) of the Act

27 June 2024

Cancellation by sponsor

Requested by Lupin Australia Pty Limited

Pages

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.